During development and in the vascularization of tumors inductive signaling leads to the formation of capillaries throughout the new-forming tissues (1, 2) . Inhibitors who regulate proliferation, migration, differentiation of endothelial cells, degradation of the extracellular matrix, and tube formation finely tune this complex process, known as angiogenesis (3) (4) (5) . The prototype of angiogenic factors is represented by vascular endothelial growth factor (VEGF) A, also known as vascular permeability factor. VEGF-A induces endothelial cell differentiation and is essential for embryonic vessel development (4, 6, 7) . It belongs to a multigene family of angiogenic factors in which several new members were discovered recently. It generally is thought that each member of this family plays a specific role in the angiogenic process (2) . In addition to VEGF-A, this family includes the placental growth factor (PlGF), VEGF-B͞VRF, VEGF-C͞VRP, c-fosinduced growth factor (Figf)͞VEGF-D, and VEGF-E (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . All of these factors show a conserved cysteine-rich domain characteristic of the family. Differences in the patterns of expression suggest a specific role for at least some of the factors in the vascularization of different tissues. Plgf is expressed mostly in the placenta, whereas VEGF-B is prevalent in skeletal and cardiac muscle tissues (12, 19) . These two factors can form heterodimers with VEGF-A adding an additional level of specificity (12, 20) . Interestingly, VEGF-C is involved in both blood and lymphatic vessel growth (21, 22) .
Figf͞Vegf-D initially was identified by using a differential screening strategy aimed at the identification of new c-fosresponsive genes in mouse fibroblasts and therefore named c-fos-induced growth factor (15) . Its human orthologue shares 84% identity and was named VEGF-D because it encodes for a secreted protein whose primary sequence is most similar to VEGF-C (16, (23) (24) (25) . Both VEGF-C and VEGF-D are recognized by VEGF receptors (VEGFR)-2 and -3, which are present on endothelial cells (14, 23) . In mouse embryos Figf͞Vegf-D is expressed in several organs, including limb buds, teeth, heart, and pituitary as well as lung and kidney mesenchyme, liver, derma, and periosteum of the vertebral column that partially overlaps Vegf-C expression (26, 27) . In cultured fibroblasts Figf͞Vegf-D regulation differs from VEGF-C. Whereas the expression of Figf͞Vegf-D depends on c-fos (15) , VEGF-C is induced by serum, tumor promoter phorbol myristate 13-acetate, IL-1␤, and tumor necrosis factor ␣, and its expression is independent from c-fos (15, 28, 29) .
We produced a recombinant form of mature mouse Figf͞ Vegf-D and analyzed its biological activity both in vivo and in vitro. Figf͞Vegf-D, expressed in Chinese hamster ovary (CHO) cells or purified from yeast, is a potent angiogenic factor in rabbit cornea assays. In vitro it activates tyrosine phosphorylation of VEGFR-2 and VEGFR-3 present on human umbilical cord vein endothelial cells (HUVECs) and on the Kaposi's sarcoma immortalized cell line (KS-IMM). In KS-IMM cells Figf͞Vegf-D induces proliferation and chemotaxis. In HUVECs Figf͞Vegf-D induces growth and morphological changes within a three-dimensional matrix.
MATERIALS AND METHODS

Expression of Figf͞Vegf-D.
To express the mature factor in CHO cells, the Figf͞Vegf-D cDNA with a segment coding for the FLAG octapeptide (IBI͞Kodak) at C terminal was amplified by PCR and inserted into the mammalian expression vector pcDNA3 (Invitrogen) under the control of the cytomegalovirus promoter (construct LM357). CHO cells were transfected with LM357 by using calcium phosphate precipitation. Stable clones were selected in DMEM containing 10% FCS and 800 g͞ml G418. To assay the presence of Figf͞ Vegf-D in CHO supernatants, isolated clones were grown in DMEM containing 2% FCS and 800 g͞ml G418 and analyzed by ELISA using anti-Figf͞Vegf-D rabbit polyclonal antiserum (15 In Vivo Angiogenic Assay. The angiogenic activity of Figf͞ Vegf-D was assayed in vivo by using the rabbit cornea assay previously described (31) . Corneal assays were performed in male New Zealand albino rabbits (Charles River, Calco, Lecco, Italy) in accordance with the guideline of the European Economic Community for Animal Care and Welfare (EEC Law No. 86͞609). Briefly, after being anaesthetized with sodium pentotal (30 mg͞Kg), a micro pocket (1.5 ϫ 3 mm) was surgically produced by using a pliable iris spatula 1.5 mm wide in the lower half of the cornea. The cell suspension (from 2.5 to 4 ϫ 10 5 cells͞5 ml) or slow-release pellets of Elvax-40 (DuPont) containing the purified growth factor were implanted into the micro pocket. Subsequently daily observation of the implants was made with a slit lamp stereomicroscope without anesthesia. An angiogenic response was scored positive when budding of vessels from the limbal plexus occurred after 4 days and capillaries progressed to reach the implanted pellet according to the scheme previously reported (32) . The potency of angiogenic activity was evaluated on the basis of the number and growth rate of newly formed capillaries, and an angiogenesis score was calculated as described (32) . Corneas were removed at the end of the experiment as well as at defined intervals after surgery and͞or treatment and fixed in formalin for histological examination. A minimum of four independent experiments was performed for each condition.
Cell Cultures. Human endothelial cells were isolated from umbilical cord vein by collagenase treatment as described (33) and used at passage 1-4. KS-IMM cells were derived from a non-AIDS patient and are immortalized without signs of senescence after more than 120 in vitro passages. This cell line shares common markers and similar biological behavior with typical KS ''spindle cells'' (34) . Cells were grown on gelatincoated plastic, in medium M 199 supplemented with 20% heat-inactivated FCS, penicillin (100 units͞ml), streptomycin (50 g͞ml), heparin (50 g͞ml), and bovine brain extract (100 g͞ml) (Life Technologies, Milan, Italy).
In Vitro Angiogenesis. Because Matrigel can induce spontaneously in vitro angiogenesis, we tested more preparations and used batches devoid of this activity. Fifty microliters of Matrigel (Collaborative Research, lot 901448) (35) was added per well of 96-well tissue culture plates and allowed to gel at 37°C for 10 min. HUVECs were starved for 24 h in M199 with 1% FCS before being harvested in PBS-EDTA. Cells (10 4 ) were gently added to each of triplicate wells and allowed to adhere to the gel coating for 30 min at 37°C. Then, medium was replaced with indicated concentrations of Figf͞Vegf-D. The plates were monitored after 24 h and photographed with a Canon microscope. Each experiment was repeated at least three times with identical results.
Immunoprecipitation and Western Blotting. Subconfluent cultures were starved as above and then cells were stimulated with the indicated concentrations of Figf͞Vegf-D for 10 min at room temperature. Positive control was done by incubating cells with sodium orthovanadate (0.1 mM H 2 O 2 , 1 mM Na 3 OV 4 ) for 20 min at 37°C. After three washes with cold PBS containing 1 mM sodium orthovanadate, cells were lysed for 20 min on ice in 50 mM Tris⅐HCl (pH 7.4), 150 mM NaCl, 1 mM Ne 3 VO 4 , 1 mM PMSF, 0.1 mM ZnCl 2 , 1% Triton. Lysates (1 mg of total proteins) were incubated at 4°C for 2 h with 100 l of a 50% solution of protein A-Sepharose (AmershamPharmacia Biotech) in 50 mM Tris⅐HCl (pH 7.4), 150 mM NaCl, and anti-VEGFR-2 (Santa Cruz Biotechnology, sc-504) or anti-VEGFR-3 (Santa Cruz Biotechnology, sc-321). Immunoprecipitates were washed four times with lysis buffer and analyzed by 8% SDS͞PAGE. Proteins were transferred onto a nylon membrane [poly(vinylidene difluoride), Millipore] and analyzed by immunoblotting with antiphosphotyrosine mAb (Upstate Biotechnology, Lake Placid, NY). Staining was performed by a chemiluminescence assay (ECL, AmershamPharmacia Biotech).
Cell Growth Assay. HUVECs (2.5 ϫ 10 3 ) or KS-IMM cells were plated in 96-well plates (Costar) coated with gelatin (Difco; 0.05%, for 1 h at 22°C) in M199 medium containing 20% FCS (Irvine Scientific). After 24 h the medium was removed and replaced with M199 containing 1% FCS with or without Figf͞Vegf-D; fresh factor was added every 2 days. Endothelial cell numbers were estimated after staining with crystal violet by a colorimetric assay described by Keung et al. (36) .
Chemotaxis Assay. Chemotaxis assays on HUVECs and KS-IMM were performed as described (33, 37) with the Boyden chamber technique using a 48-well micro chemotaxis chamber. Polyvinylpyrrolidone-free polycarbonate filters (Nucleopore, Corning-Costar) with a pore size of 5 m were coated with 1% gelatin for 10 min at room temperature and equilibrated in M199 supplemented with 1% FCS. Indicated concentrations of purified Figf͞Vegf-D were placed in the lower compartment of a Boyden chamber. Subconfluent cultures were starved as above, harvested in PBS (pH 7.4) with 10 mM EDTA, washed once in PBS, and resuspended in M199 containing 1% FCS, at a final concentration of 2.5 ϫ 10 6 cells͞ml. After placing the filter between the lower and upper chambers, 50 l of the cell suspension was seeded in the upper compartment. Cells were allowed to migrate for 7 h at 37°C in a humidified atmosphere with 5% CO 2 . The filter then was removed, and cells on the upper side were scraped with a rubber policeman. Migrated cells were fixed in methanol, stained with Giemsa solution (Diff-Quick, Baxter Diagnostics, Rome) and counted from five random high-power fields (magnification ϫ100) in each well. Each experimental point was studied in triplicate.
RESULTS
Induction of Angiogenesis in Vivo.
Mature VEGF-C and Figf͞VEGF-D factors are generated by proteolytic cleavages of both of the N-and C-terminal domains during secretion (15, 23, 38) . To obtain recombinant mature Figf͞Vegf-D we generated CHO clones by stable transfection of constructs containing the mouse Figf͞Vegf-D cDNA truncated at the Cterminal proteolytic site (38) . To assess in vivo the angiogenic activity of increasing concentrations of the recombinant protein administered to avascular tissue two clones expressing different levels of secreted Figf͞Vegf-D were selected for implantation into rabbit corneas. These clones secrete in the culture medium Figf͞Vegf-D in two main forms of molecular mass of 30 and 21 kDa, respectively (Fig. 1A) . Both clone 65 and clone 79 induced corneal vascularization whereas the CHO mock transfectant clone did not show any angiogenic (Fig. 1B) . Although a direct dose response could not be made in this assay, the efficiency of the angiogenic response correlated with the amount of growth factor released in vitro as clone 79 secreted about 5-fold more Figf͞Vegf-D than clone 65 in the same conditions (Fig. 1 A) . Consistently, neovascular growth induced by clone 79 was more efficient and persisted in 100% of the implants whereas clone 65 did so in only 30% of corneas (Fig. 1B) . This angiogenic activity also was suggested by the direct correlation between neovascular growth observed and the number of cells implanted into corneal micro pocket (data not shown). The angiogenic response obtained with clone 79 (Fig. 1C) (Fig. 2 A) and it is sensitive to endoglycosidase H (not shown).
Figf͞Vegf-D purified to homogeneity was analyzed in the corneal micro pocket assay in vivo. (Fig. 2D ) when used at doses of 300-400 ng.
Corneal angiogenesis induced by either Figf͞Vegf-D or VEGF-A was noninflammatory (not shown).
Figf͞Vegf-D Induces in Vitro Angiogenesis. Studying endothelial cell behavior in a three-dimensional culture system, consisting of extra cellular matrix proteins, allows for in vitro conditions that more closely mimic the in vivo environment permissive for cell differentiation into capillary-like structures. This assay system is called in vitro angiogenesis (40) . To examine whether Figf͞Vegf-D induces in vitro morphological changes resembling of capillary like-structure formation, endothelial cells were plated on a three-dimensional matrix of Matrigel (41) Proliferation of both cell types was stimulated in a dosedependent manner (Fig. 5 A and B) . The effect was investigated in a range of concentrations between 5 and 100 ng͞ml and was maximal at 50 ng͞ml for both cell types. Interestingly, when suboptimal concentrations of VEGF-A 165 and Figf͞ Vegf-D were coadded to HUVECs the resulting proliferation was higher than the treatment of each alone (not shown).
The (2, 10, 42, 43) . The generation of VEGF-A knockout mice demonstrated that this factor is essential for angiogenesis during development (6, 7) . Thus, simple redundancy of all members of the family is unlikely. We favor the hypothesis that the complex process of angiogenesis normally requires the cooperation of multiple factors and the experimental overexpression of some key members is able to trigger the process both directly and indirectly, inducing the expression of other factors. Each of these factors shows a peculiar pattern of expression, suggesting that a complex balance of factors in different developing organs may be relevant. Moreover, the biological function of VEGFs may not be limited to angiogenesis. For instance, fibroblast growth factors not only induce angiogenesis, but are also regulators of embryonic development, influencing the formation of several structures including body axis, limbs, heart, and lung differentiation (44) (45) (46) (47) . Similarly, the expression of Figf͞Vegf-D in tissues like the pituitary, the developing teeth, lung mesenchyme, and limb buds (26) suggests that Figf͞Vegf-D, in addition to playing a role in angiogenesis, could be involved in specific inductive signaling in these developing organs.
Figf͞Vegf-D and VEGF-C share striking similarities in their primary sequence and posttranslational modifications, and most importantly, both factors are recognized by VEGFR-2 and VEGFR-3 present on vascular and lymphatic vessels (14, 23) . By using porcine aortic endothelial cells selectively overexpressing VEGFR-2 or VEGFR-3, it was shown recently that VEGF-C could promote migration and proliferation independently of signaling through either receptor (21) . In this study for the analysis of This discrepancy could be simply because of differences in the receptor levels or in intracellular signaling molecules, but it also could be the result of the presence of possible coreceptors that may modify the receptor affinity and modulate the response to Figf͞Vegf-D. In line with this possibility, it recently has been shown in human endothelial cells that neuropilin-1 (48) and ␣v␤3 modulate the activity of VEGFR-2. Neuropilil-1 is a coreceptor for the VEGF-A 165 isoform and the ␣v␤3 integrin associates with VEGFR-1 upon VEGF-A stimulation and regulates the level of tyrosine phosphorylation of the receptor (49) .
Figf͞Vegf-D differs from all other members of the VEGF family because it is the only angiogenic factor regulated by the nuclear oncogene c-fos (15) . This unique regulation of Figf͞ Vegf-D may be relevant both during development and in tumor progression because c-fos is involved not only in transformation but also in the regulation of cell growth and differentiation of various tissues (50, 51) . Tumors that develop in c-fosdeficient mice appear devoid of vascularization although, in 
